Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Liver Diseases

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 87 articles:
HTML format



Single Articles


    November 2022
  1. TAKEDA S, Namisaki T, Tsuji Y, Fujimoto Y, et al
    Initial Experience With Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma: A Real-world Retrospective Study.
    Anticancer Res. 2022;42:5465-5473.
    PubMed     Abstract available


  2. TAKEDA K, Kikuchi Y, Sawada YU, Kumamoto T, et al
    Efficacy of Adjuvant Chemotherapy Following Curative Resection of Colorectal Cancer Liver Metastases.
    Anticancer Res. 2022;42:5497-5505.
    PubMed     Abstract available


  3. YUEH TC, Tsao HY, Chien WC, Tsai CW, et al
    The Contribution of Matrix Metalloproteinase-7 Promoter Genotypes to Hepatocellular Carcinoma Susceptibility.
    Anticancer Res. 2022;42:5275-5282.
    PubMed     Abstract available


  4. HUANG G, Howard LN, Alonsozana E, Sill D, et al
    Molecular Characteristics and Immunogenomic Profiling of Cholangioblastic Variant of Intrahepatic Cholangiocarcinoma in a 68-year-old Patient.
    Anticancer Res. 2022;42:5475-5478.
    PubMed     Abstract available


  5. SASAKI T, Shigeta K, Kitahara S, Suzuki Y, et al
    Inhibition of STAT3 Promotes Effector T Cell Infiltration But also Immunosuppression in the HCC Tumor Microenvironment.
    Anticancer Res. 2022;42:5205-5215.
    PubMed     Abstract available


  6. SCHMITZ V, Bauerschmitz G, Gallwas J, Grundker C, et al
    Suppression of G Protein-coupled Estrogen Receptor 1 (GPER1) Enhances the Anti-invasive Efficacy of Selective ERbeta Agonists.
    Anticancer Res. 2022;42:5187-5194.
    PubMed     Abstract available


  7. KIM SH, Song SE, Baik H, Hur DY, et al
    15-Prostaglandin Dehydrogenase Inhibition Enhances Colon Cancer Metastasis by Up-regulation of Epithelial-to-Mesenchymal Transition Genes.
    Anticancer Res. 2022;42:5385-5396.
    PubMed     Abstract available


  8. KOMATSU S, Yano Y, Kido M, Kuramitsu K, et al
    Rechallenge With Lenvatinib After Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma.
    Anticancer Res. 2022;42:5479-5486.
    PubMed     Abstract available


  9. YAMAMURA K, Beppu T, Inoue K, Matsumura K, et al
    Vater Papilla-preserving Strategy for Advanced Hepatocellular Carcinoma With Excessive Bile Duct Tumor Thrombus.
    Anticancer Res. 2022;42:5663-5670.
    PubMed     Abstract available


    October 2022
  10. HUANG J, Xi Q, Xiong J, Peng H, et al
    Micro RNA miR-1303 Promotion of Proliferation, Migration and Invasion of Human Liver Cancer Cells Is Enhanced by Low Talin 1 (TLN1) Expression.
    Anticancer Res. 2022;42:4715-4725.
    PubMed     Abstract available


  11. NAGATA K, Sasaki R, Iwatsu S, Fukushima M, et al
    Long-term Outcomes and Prognostic Factors of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma.
    Anticancer Res. 2022;42:5001-5007.
    PubMed     Abstract available


  12. FUJIMOTO Y, Namisaki T, Takeda S, Murata K, et al
    Leaky Gut and Severe Adverse Events in Advanced Hepatocellular Carcinoma Treated With Lenvatinib.
    Anticancer Res. 2022;42:4895-4905.
    PubMed     Abstract available


  13. HANAKI T, Goto K, Morimoto M, Murakami Y, et al
    Surgical Administration of Indocyanine Green in Hepatectomy for Improved Bile Leakage Detection.
    Anticancer Res. 2022;42:4787-4793.
    PubMed     Abstract available


  14. UTSUMI M, Inagaki M, Kitada K, Tokunaga N, et al
    Lymphocyte-to-C-Reactive Protein Ratio Predicts Prognosis in Patients With Colorectal Liver Metastases Post-hepatic Resection: A Retrospective Study.
    Anticancer Res. 2022;42:4963-4971.
    PubMed     Abstract available


    September 2022
  15. NANASHIMA A, Tanoue Y, Hiyoshi M, Imamura N, et al
    Prognostic Value of Repeat Hepatectomy for Hepatocellular Carcinoma Patients.
    Anticancer Res. 2022;42:4553-4561.
    PubMed     Abstract available


  16. CHEN CT, Hsu CH, Cheng AL, Shao YY, et al
    Expanding Sorafenib Treatment for Hepatocellular Carcinoma Beyond Barcelona Clinic Liver Cancer Stage C Patients: A National Study.
    Anticancer Res. 2022;42:4461-4470.
    PubMed     Abstract available


  17. TAN C, Fisher OM, Huang L, Alzahrani N, et al
    Comparison of Microwave and Radiofrequency Ablation in the Treatment of Pulmonary Metastasis of Colorectal Cancer.
    Anticancer Res. 2022;42:4563-4571.
    PubMed     Abstract available


  18. CRISTAUDO AT, Jennings SB, Morris DL
    Comparison of Proportion of Elevated Carcinoembryonic Antigen Levels in Patients With Appendiceal and Colorectal Adenocarcinoma: A Systematic Review and Meta-analysis.
    Anticancer Res. 2022;42:4217-4235.
    PubMed     Abstract available


    August 2022
  19. SASAKI S, Nomura Y, Sudo T, Sakai H, et al
    Hematogenous Dissemination of Tumor Cells in Hepatocellular Carcinoma: Comparing Anterior and Non-anterior Approach Hepatectomy.
    Anticancer Res. 2022;42:4129-4137.
    PubMed     Abstract available


  20. IMAI N, Ishigami M, Oie Y, Kumagai M, et al
    Effectiveness of Porous Glass Membrane Pumping Emulsification Device in Transarterial Chemoembolization for Solitary Hepatocellular Carcinoma.
    Anticancer Res. 2022;42:3947-3951.
    PubMed     Abstract available


  21. SHIRAHAMA N, Goto Y, Sakai H, Fukutomi S, et al
    Liberal Application of Portal Vein Embolization for Right Hepatectomy Against Hepatocellular Carcinoma: Strategy to Achieve Zero Mortality for a Damaged Liver.
    Anticancer Res. 2022;42:4089-4095.
    PubMed     Abstract available


  22. WAKAME K, Sato K, Kasai M, Kikuchi E, et al
    Oral Administration of Mulberry (Morus alba L.) Leaf Powder Prevents the Development of Hepatocellular Carcinoma in Stelic Animal Model (STAM) Mice.
    Anticancer Res. 2022;42:4055-4062.
    PubMed     Abstract available


  23. JU M, Aoyama T, Komori K, Tamagawa H, et al
    The Albumin-Bilirubin Score Is a Prognostic Factor for Gastric Cancer Patients Who Receive Curative Treatment.
    Anticancer Res. 2022;42:3929-3935.
    PubMed     Abstract available


  24. NOMURA Y, Akiba J, Yano H, Akagi Y, et al
    Fatty Liver Does Not Increase the Risk of Postoperative Liver Damage Following Hepatectomy.
    Anticancer Res. 2022;42:4159-4164.
    PubMed     Abstract available


    July 2022
  25. KANG BY, Kim SM, Hur W, Roh PR, et al
    Enhanced Tumoricidal Immune Responses by Transarterial Chemotherapy Using Novel Nanocomplexes in a Rat Liver Cancer Model.
    Anticancer Res. 2022;42:3463-3473.
    PubMed     Abstract available


  26. NAKASEKO Y, Furukawa K, Haruki K, Onda S, et al
    Standardized and Feasible Laparoscopic Approach for Tumors Located in the Caudate Lobe.
    Anticancer Res. 2022;42:3621-3625.
    PubMed     Abstract available


  27. HUDSON JM, Singh S, Milot L, Patel C, et al
    Dynamic Contrast-enhanced CT to Evaluate Early Response in Neuroendocrine Liver Metastases Treated With Everolimus and Radiation.
    Anticancer Res. 2022;42:3523-3527.
    PubMed     Abstract available


    June 2022
  28. MATSUMURA K, Yamamura K, Oda E, Akahoshi S, et al
    Successful Treatment of Intrahepatic Cholangiocarcinoma With Liver/Lung Metastasis and Peritoneal Dissemination After Liver Resection.
    Anticancer Res. 2022;42:3209-3215.
    PubMed     Abstract available


  29. HIDAKA M, Hara T, Soyama A, Sasaki R, et al
    The Outcome of Conversion Liver Resection Surgery by Lenvatinib Treatment: A Single Center Experience.
    Anticancer Res. 2022;42:3049-3054.
    PubMed     Abstract available


    May 2022
  30. HSIEH CH, Yeh CT, Huang YH, Lai MW, et al
    Circulating Tumor Cells Derived from Advanced Hepatocellular Carcinoma Rapidly Develop Resistance to Cytotoxic Chemotherapy.
    Anticancer Res. 2022;42:2479-2486.
    PubMed     Abstract available


  31. KUMAMOTO T, Matsuyama R, Takeda K, Sawada YU, et al
    Surgical Indications for Huge Hepatocellular Carcinoma.
    Anticancer Res. 2022;42:2573-2581.
    PubMed     Abstract available


  32. YANG CJ, Wu MH, Tsai JJ, Hsu FT, et al
    Inactivation of AKT/ERK Signaling and Induction of Apoptosis Are Associated With Amentoflavone Sensitization of Hepatocellular Carcinoma to Lenvatinib.
    Anticancer Res. 2022;42:2495-2505.
    PubMed     Abstract available


    April 2022
  33. KUZUYA T, Kawabe N, Hashimoto S, Funasaka K, et al
    Clinical Outcomes of Ramucirumab as Post-treatment Following Atezolizumab/Bevacizumab Combination Therapy in Advanced Hepatocellular Carcinoma.
    Anticancer Res. 2022;42:1905-1910.
    PubMed     Abstract available


  34. HANAKI T, Sunaguchi T, Goto K, Morimoto M, et al
    The Significance of Surgical Intervention for Metasynchronous Liver Metastasis in Gastric Cancer: A Single-centre Analysis.
    Anticancer Res. 2022;42:2177-2184.
    PubMed     Abstract available


  35. TOMITA K, Chiba N, Ochiai S, Gunji T, et al
    Prognostic Impact of N2 of the Primary Tumour in Surgical Resection for Colorectal Liver Metastases.
    Anticancer Res. 2022;42:1997-2001.
    PubMed     Abstract available


    March 2022
  36. KOMATSU S, Yano Y, Fujishima Y, Ishida J, et al
    Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
    Anticancer Res. 2022;42:1403-1412.
    PubMed     Abstract available


  37. HAMAYA S, Fujihara S, Iwama H, Fujita K, et al
    Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells.
    Anticancer Res. 2022;42:1263-1275.
    PubMed     Abstract available


  38. MATSUMURA K, Yamamura K, Miyamoto H, Hara Y, et al
    Highly Advanced Colorectal Liver Metastases Successfully Treated With Fluorouracil Plus Leucovorin Monotherapy and Microwave Ablation.
    Anticancer Res. 2022;42:1645-1651.
    PubMed     Abstract available


  39. BARAK V, Kalickman I, Pe'er J
    sIL-2R- an Immuno-biomarker for Prediction of Metastases in Uveal Melanoma.
    Anticancer Res. 2022;42:1447-1453.
    PubMed     Abstract available


  40. TASHIRO Y, Aoki T, Hirai T, Koizumi T, et al
    Indocyanine Green Labeling of Tumors in the Liver Recurring After Radiofrequency Ablation Enables Complete Resection by Fluorescence-guided Surgery.
    Anticancer Res. 2022;42:1345-1350.
    PubMed     Abstract available


    February 2022
  41. ICHIDA A, Akamatsu N, Nagata R, Mihara Y, et al
    Efficacy and Safety of Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Living Donor Liver Transplantation: A Report of Two Cases.
    Anticancer Res. 2022;42:1161-1167.
    PubMed     Abstract available


  42. ABE K, Maeda-Minami A, Ishizu T, Iwata S, et al
    Risk Factors for Hepatic Toxicity of High-dose Methotrexate in Patients With Osteosarcoma.
    Anticancer Res. 2022;42:1043-1050.
    PubMed     Abstract available


  43. FUJITA N, Handa A, Park JM
    Peritumoral Hyperintensity at Hepatobiliary Phase Gadoxetic Acid-enhanced MRI in Hepatic Neuroendocrine Tumors.
    Anticancer Res. 2022;42:911-917.
    PubMed     Abstract available


  44. JANG WI, Kim MS, Jeong JH, Kim W, et al
    Enhancement of Radiation Response Associated With Metformin in Hepatocellular Carcinoma: Preclinical Animal and Clinical Cohort Study.
    Anticancer Res. 2022;42:867-876.
    PubMed     Abstract available


  45. ZIOGAS IA, Schmitz R, Moris D, Vatsaas CJ, et al
    The Role of Surgery for Pancreatic Neuroendocrine Tumors.
    Anticancer Res. 2022;42:629-639.
    PubMed     Abstract available


    January 2022
  46. YAMAMURA K, Beppu T, Miyata T, Okabe H, et al
    Conversion Surgery for Hepatocellular Carcinoma Following Molecular Therapy.
    Anticancer Res. 2022;42:35-44.
    PubMed     Abstract available


  47. AURELLO P, Minervini A, Pace M, D'Angelo F, et al
    The Role of Surgery in the Treatment of Metachronous Liver Metastasis from Gastric Cancer: A Systematic Review.
    Anticancer Res. 2022;42:25-33.
    PubMed     Abstract available


  48. INOUE KI, Yamagishi H, Jojima T, Inoue T, et al
    Development of Non-alcoholic Steatohepatitis and Nodular Regenerative Hyperplasia in C57BL/6J Mice Fed a Fructose-containing Western Diet.
    Anticancer Res. 2022;42:609-617.
    PubMed     Abstract available


  49. JUNG JY, Koh SA, Lee KH, Kim JR, et al
    14-3-3 Sigma Protein Contributes to Hepatocyte Growth Factor-mediated Cell Proliferation and Invasion via Matrix Metalloproteinase-1 Regulation in Human Gastric Cancer.
    Anticancer Res. 2022;42:519-530.
    PubMed     Abstract available


  50. MIZUOCHI S, Akiba J, Kondo R, Kusano H, et al
    Clinicopathological Analysis of Non-B Non-C Hepatocellular Carcinoma Focusing on Cellular Proliferation.
    Anticancer Res. 2022;42:449-457.
    PubMed     Abstract available


  51. HARIMOTO N, Itoh S, Yamanaka T, Hagiwara K, et al
    Mac-2 Binding Protein Glycosylation Isomer as a Prognostic Marker for Hepatocellular Carcinoma With Sustained Virological Response.
    Anticancer Res. 2022;42:245-251.
    PubMed     Abstract available


  52. SHIMOZATO N, Namisaki T, Okano A, Ohana M, et al
    Efficacy and Safety of Lenvatinib for Patients With Advanced Hepatocellular Carcinoma: A Retrospective, Real-world Study Conducted in Japan.
    Anticancer Res. 2022;42:173-183.
    PubMed     Abstract available


    November 2021
  53. IMAI N, Yokoyama S, Yamamoto K, Ito T, et al
    Safety and Efficacy of Glass Membrane Pumping Emulsification Device in Transarterial Chemoembolization for Hepatocellular Carcinoma: First Clinical Outcomes.
    Anticancer Res. 2021;41:5817-5820.
    PubMed     Abstract available


  54. OMIYA S, Komatsu S, Kido M, Kuramitsu K, et al
    Impact of Sarcopenia as a Prognostic Factor on Reductive Hepatectomy for Advanced Hepatocellular Carcinoma.
    Anticancer Res. 2021;41:5775-5783.
    PubMed     Abstract available


  55. ADACHI Y, Yamamura K, Yumoto S, Higashi T, et al
    Far-advanced Colorectal Liver Metastases Successfully Managed With Modified ALPPS and Radiofrequency Ablation in Combination With Chemotherapy.
    Anticancer Res. 2021;41:5855-5861.
    PubMed     Abstract available


  56. FURUKAWA K, Onda S, Taniai T, Hamura R, et al
    Risk Factors and Overcoming Strategies of Surgical Site Infection After Hepatectomy for Colorectal Liver Metastases.
    Anticancer Res. 2021;41:5651-5656.
    PubMed     Abstract available


  57. MASATSUNE S, Kimura K, Kashiwagi S, En W, et al
    Impact of Intraoperative Blood Loss and Blood Transfusion on the Prognosis of Colorectal Liver Metastasis Following Curative Resection.
    Anticancer Res. 2021;41:5617-5623.
    PubMed     Abstract available


  58. TAGO T, Katsumata K, Udou R, Kasahara K, et al
    Significance of Radiofrequency Ablation for Unresectable Colorectal Cancer With Liver Metastases.
    Anticancer Res. 2021;41:5539-5547.
    PubMed     Abstract available


  59. TSOCHANTARIDIS I, Voulgaridou GP, Giatromanolaki A, Koukourakis MI, et al
    Profiling of Aldehyde Dehydrogenase Isoforms in In Vitro Formed Tumorspheres.
    Anticancer Res. 2021;41:5481-5488.
    PubMed     Abstract available


    October 2021
  60. ODA E, Yamamura K, Hara Y, Matsumura K, et al
    Intrahepatic Cholangiocarcinoma Coexisting With Multiple Bile Duct Adenoma Treated as Liver Metastasis from a Pancreatic Neuroendocrine Tumor.
    Anticancer Res. 2021;41:5249-5254.
    PubMed     Abstract available


  61. KIM M, Kim HC, Chung JW
    Chemoembolization for Hepatocellular Carcinoma in Patients With Inferior Vena Caval/Right Atrial Tumor Thrombi Without Hepatic Vein Invasion.
    Anticancer Res. 2021;41:5241-5247.
    PubMed     Abstract available


  62. MOON H, Park H, Ro SW
    c-Myc-driven Hepatocarcinogenesis.
    Anticancer Res. 2021;41:4937-4946.
    PubMed     Abstract available


    September 2021
  63. KOMATSU S, Yano Y, Kido M, Kuramitsu K, et al
    Lenvatinib Rechallenge After Ramucirumab Treatment Failure for Hepatocellular Carcinoma.
    Anticancer Res. 2021;41:4555-4562.
    PubMed     Abstract available


  64. OKAMOTO H, Shiba S, Iino H, Sudoh M, et al
    Tumor Vascular Microenvironment of Colorectal Hepatic Metastasis and Chemotherapy Response.
    Anticancer Res. 2021;41:4505-4513.
    PubMed     Abstract available


  65. TSUNEMATSU M, Onda S, Yanagaki M, Okui N, et al
    How to Perform Curative Laparoscopic Hepatectomy for Intraoperatively Unidentified Hepatocellular Carcinoma.
    Anticancer Res. 2021;41:4411-4416.
    PubMed     Abstract available


  66. TOKUDA K, Morine Y, Miyazaki K, Yamada S, et al
    Frailty Can Predict Prognosis After Hepatectomy in Patients With Colorectal Liver Metastasis.
    Anticancer Res. 2021;41:4637-4644.
    PubMed     Abstract available


    August 2021
  67. YAMANAKA M, Hayashi M, Yamada S, Sonohara F, et al
    A Possible Definition of Oligometastasis in Pancreatic Cancer and Associated Survival Outcomes.
    Anticancer Res. 2021;41:3933-3940.
    PubMed     Abstract available


  68. OURA K, Aoki T, Tashiro Y, Matsuda K, et al
    Indocyanine Green Fluorescence Image-guided Laparoscopic Hepatectomy Enabled Resection of a Tumor Invisible With Ultrasonography.
    Anticancer Res. 2021;41:3867-3869.
    PubMed     Abstract available


    July 2021
  69. KUBO H, Ikoma H, Yamamoto Y, Morimura R, et al
    Therapeutic Strategy of Colorectal Liver Metastasis Using Modified-JHBPS Nomogram.
    Anticancer Res. 2021;41:3657-3665.
    PubMed     Abstract available


  70. VIEIRA JF, Peixoto AP, Murta EFC, Michelin MA, et al
    Prophylactic Dendritic Cell Vaccination in Experimental Breast Cancer Controls Immunity and Hepatic Metastases.
    Anticancer Res. 2021;41:3419-3427.
    PubMed     Abstract available


    June 2021
  71. AU KY, Chan KK, Lo RC
    A Clinicopathological Study of Young-onset Hepatocellular Carcinoma.
    Anticancer Res. 2021;41:2933-2944.
    PubMed     Abstract available


    May 2021
  72. YAMAMURA K, Beppu T, Oda E, Sato N, et al
    Hepatic Inflammatory Pseudotumor Mimicking Malignant Tumor With Rare Onset of Intra-abdominal Hemorrhage.
    Anticancer Res. 2021;41:2727-2732.
    PubMed     Abstract available


  73. KIM HC, Choi JW, Lee M, Kim YJ, et al
    Yttrium-90 Radioembolization for Hepatocellular Carcinoma: Virtual Tumor Absorbed Dose as a Predictor of Complete Response.
    Anticancer Res. 2021;41:2625-2635.
    PubMed     Abstract available


  74. YAMAMOTO T, Imai N, Yamamoto K, Ito T, et al
    Tolerability of Molecular-targeted Agents for Hepatocellular Carcinoma Treatment in Haemophiliacs.
    Anticancer Res. 2021;41:2569-2573.
    PubMed     Abstract available


  75. ISHIGAMI I, Shuwari N, Kaminade T, Mizuguchi H, et al
    A TGFbeta Signaling Inhibitor, SB431542, Inhibits Reovirus-mediated Lysis of Human Hepatocellular Carcinoma Cells in a TGFbeta-independent Manner.
    Anticancer Res. 2021;41:2431-2440.
    PubMed     Abstract available


  76. SHIBUTANI M, Kimura K, Kashiwagi S, Wang EN, et al
    Elevated Postoperative Levels of Serum C-reactive Protein Are Associated With Shorter Long-term Survival After Resection of Colorectal Liver Metastases, Regardless of the Occurrence of Infectious Complications.
    Anticancer Res. 2021;41:2605-2610.
    PubMed     Abstract available


  77. NISHIKAWA H, Fukunishi S, Asai A, Nishiguchi S, et al
    Obesity and Liver Cancer in Japan: A Comprehensive Review.
    Anticancer Res. 2021;41:2227-2237.
    PubMed     Abstract available


    April 2021
  78. MAESAKA K, Sakamori R, Yamada R, Tahata Y, et al
    Efficacy of Ramucirumab Versus Sorafenib as Subsequent Treatment for Hepatocellular Carcinoma.
    Anticancer Res. 2021;41:2187-2192.
    PubMed     Abstract available


  79. FURUKAWA K, Haruki K, Yasuda J, Onda S, et al
    Strategies to Perform Curative Laparoscopic Repeat Hepatectomy for Recurrent Liver Tumors After Open Right Lobectomy.
    Anticancer Res. 2021;41:2171-2175.
    PubMed     Abstract available


  80. SASAKI R, Fukushima M, Haraguchi M, Miuma S, et al
    Liver Function in Older Patients With Unresectable Hepatocellular Carcinoma After Administration of Lenvatinib.
    Anticancer Res. 2021;41:2025-2032.
    PubMed     Abstract available


  81. SHAO C, Shao PP, Chen WT, Lin CC, et al
    Direct-acting Antiviral Therapy Improves the Outcome of Chronic Hepatitis C/intermediate-stage B Hepatocellular Carcinoma Patients.
    Anticancer Res. 2021;41:2007-2016.
    PubMed     Abstract available


  82. YASUHARA Y, Komatsu S, Kuramitsu K, Kido M, et al
    Feasibility of Reductive Hepatectomy in Patients With BCLC B and C Hepatocellular Carcinoma.
    Anticancer Res. 2021;41:1975-1983.
    PubMed     Abstract available


  83. LEE GW, Hur W, Kim JH, Park DJ, et al
    Nardostachys jatamansi Root Extract Attenuates Tumor Progression in Hepatocellular Carcinoma via Inhibition of ERK/STAT3 Pathways.
    Anticancer Res. 2021;41:1883-1893.
    PubMed     Abstract available


  84. NISHINO H, Okuno M, Seo S, Toda R, et al
    Sinusoidal Obstruction Syndrome Promotes Liver Metastatic Seeding of Colorectal Cancer Cells in a Rat Model.
    Anticancer Res. 2021;41:1803-1810.
    PubMed     Abstract available


  85. SHIBA S, Shibuya K, Okamoto M, Okano N, et al
    Carbon-ion Radiotherapy for Oligometastatic Colorectal Cancer in the Liver or Lung.
    Anticancer Res. 2021;41:1997-2005.
    PubMed     Abstract available


    March 2021
  86. NAKANISHI Y, Hirota S, Hojo Y, Nakamura T, et al
    Pathological Complete Remission of Liver Metastases Correlates With Elimination of Tumor-infiltrating Tregs in Gastric Cancer.
    Anticancer Res. 2021;41:1571-1577.
    PubMed     Abstract available


  87. HIROSE Y, Sakata J, Kobayashi T, Miura K, et al
    NQO1 as a Marker of Chemosensitivity and Prognosis for Colorectal Liver Metastasis.
    Anticancer Res. 2021;41:1563-1570.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: